Clearpoint Neuro, INC Form 4 insider transactions

R. John Fletcher, a Director at ClearPoint Neuro, Inc., acquired 662 shares of common stock on July 1, 2026, as compensation for services rendered.

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., acquired 222 shares of common stock on July 1, 2026, as payment for services rendered.

ClearPoint Neuro CEO Joseph Burnett executed a Rule 10b5-1 trading plan, acquiring 20,000 shares and selling 20,000 shares.

ClearPoint Neuro, Inc. director Timothy T. Richards reported transactions involving the acquisition and disposition of company stock.

Director Matthew B. Klein reported a transaction involving the sale of 16,000 shares of ClearPoint Neuro, Inc. common stock.

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., acquired 12,820 restricted stock units on May 21, 2026, as detailed in a Form 4 filing.

Director R. John Fletcher of ClearPoint Neuro, Inc. acquired 12,820 restricted stock units on May 21, 2026, as detailed in a Form 4 filing.

ClearPoint Neuro, Inc. Director B. Kristine Johnson acquired 12,820 restricted stock units on May 21, 2026.

R. John Fletcher, a Director at ClearPoint Neuro, Inc., acquired 12,417 shares of common stock upon the vesting of restricted stock units.

ClearPoint Neuro, Inc. Director Timothy T. Richards acquired 12,417 shares of common stock upon the vesting of restricted stock units.

ClearPoint Neuro, Inc. Director B. Kristine Johnson acquired 12,417 shares of common stock upon the vesting of restricted stock units.

ClearPoint Neuro, Inc. Director Pascal E. R. Girin acquired 12,417 shares of common stock upon the vesting of restricted stock units.

Linda M. Liau, a Director at ClearPoint Neuro, Inc., has settled 12,417 restricted stock units, receiving an equivalent number of common shares.

Director R. John Fletcher acquired 1,270 shares of ClearPoint Neuro, Inc. common stock as compensation for board services.

Director Pascal E. R. Girin acquired 755 shares of ClearPoint Neuro, Inc. common stock as compensation for board services.

Director Timothy T. Richards acquired 442 shares of ClearPoint Neuro, Inc. common stock as compensation for board services.

ClearPoint Neuro's CEO and President, Joseph Burnett, has filed a Form 4 indicating a planned exercise of 20,942 stock options on March 19, 2026, at $3.24 per share, under a 10b5-1 plan.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

ClearPoint Neuro, Inc. CEO Joseph Burnett reported the settlement of restricted stock units and a subsequent tax-related sale of common stock.

ClearPoint Neuro's Chief Business Officer, L. Jeremy Stigall, acquired common stock through RSU vesting and simultaneously disposed of shares for tax withholding.

ClearPoint Neuro's COO, Mazin Sabra, saw 26,101 restricted stock units vest, leading to an acquisition of common stock and a subsequent sale of shares for tax withholding.

ClearPoint Neuro's CFO, Danilo D'Alessandro, acquired 4,145 shares of common stock through restricted stock unit vesting and subsequently sold 2,109 shares for tax obligations.

ClearPoint Neuro's Chief Business Officer, L. Jeremy Stigall, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

ClearPoint Neuro, Inc. CEO and President Joseph Burnett acquired 26,568 shares of common stock through RSU vesting and disposed of 9,533 shares to cover tax obligations.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reported a pre-planned transaction for the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, effective March 3, 2026.

ClearPoint Neuro's Chief Business Officer, L. Jeremy Stigall, acquired 8,856 shares through RSU vesting and subsequently sold 4,506 shares for tax obligations.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, settled restricted stock units, leading to an acquisition of 6,642 shares and a subsequent sale of 3,380 shares for tax purposes.

ClearPoint Neuro CEO Joseph Burnett sold 19,951 shares of common stock for a weighted average price of $15.17 per share, executed under a pre-arranged 10b5-1 trading plan.

ClearPoint Neuro, Inc.'s Chief Operating Officer, Mazin Sabra, was granted 36,818 restricted stock units under a Rule 10b5-1 plan.

ClearPoint Neuro, Inc.'s Chief Business Officer, L. Jeremy Stigall, was granted 51,546 restricted stock units, vesting over three years.